Organon, which is seeking approval of Vtama as a treatment for atopic dermatitis, said the FDA set a new target action date of March 12 for a decision after requesting the final datasets and ...

Organon said the Food and Drug Administration ... N.J., company picked up Vtama as part of its acquisition of Dermavant Sciences from Roivant Sciences last month and had been expecting a green ...

Organon is paying $175 million upfront to buy Roivant's dermatology unit Dermavant and its topical psoriasis therapy Vtama, which is also under review by the FDA for atopic dermatitis. Discover ...

Organon is paying $175 million upfront to buy Roivant's dermatology unit Dermavant and its topical psoriasis therapy Vtama, which is also under review by the FDA for atopic dermatitis. The AI ...

TD Cowen analyst Yaron Werber maintained a Buy rating on Roivant Sciences (ROIV – Research Report) today. The company’s shares ...

Organon & Co. (NYSE:OGN) shareholders are probably feeling a little disappointed, since its shares fell 3.1% to US$16.92 in the week after its latest quarterly results. Results were roughly in ...

JERSEY CITY, N.J. (AP) — JERSEY CITY, N.J. (AP) — Organon & Co. (OGN) on Thursday reported third-quarter profit of $359 million. On a per-share basis, the Jersey City, New Jersey-based company ...

Organon & Co. Price Performance Shares of OGN opened at $15.78 on Thursday. Organon & Co. has a 1-year low of $10.84 and a 1-year high of $23.10. The company has a debt-to-equity ratio of 17.73, a ...

Organon & Co (Symbol: OGN) presently has a stellar rank, in the top 10% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by investors.

Organon (OGN) announced that the FDA extended by three months the target action date of its review of the supplemental New Drug Application, or sNDA, for Vtama cream, 1% as a treatment for atopic ...